IP Verse

Crenolanib For Treating Flt3 Mutated Proliferative Disorders - EP2941251

The patent EP2941251 was granted to Arog Pharmaceuticals on Mar 7, 2018. The application was originally filed on Oct 14, 2013 under application number EP13869984A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2941251

AROG PHARMACEUTICALS
Application Number
EP13869984A
Filing Date
Oct 14, 2013
Status
Opposition Rejected
May 9, 2025
Grant Date
Mar 7, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXAL PHARMADec 7, 2018KRAUS & LEDERERADMISSIBLE
HEXAL PHARMADec 7, 2018KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004049032
DESCRIPTIONUS2005124599
DESCRIPTIONUS5990146
DESCRIPTIONUS7183414
DESCRIPTIONWO0140217
DESCRIPTIONWO02092599
DESCRIPTIONWO0232861
DESCRIPTIONWO03024931
DESCRIPTIONWO03024969
DESCRIPTIONWO03035009
DESCRIPTIONWO03037347
DESCRIPTIONWO03057690
DESCRIPTIONWO03099771
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004016597
DESCRIPTIONWO2004018419
DESCRIPTIONWO2004039782
DESCRIPTIONWO2004043389
DESCRIPTIONWO2004046120
DESCRIPTIONWO2004058749
DESCRIPTIONWO9916755

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Blood, vol. 120, no. 21-
OPPOSITION- CATHERINE C SMITH et al., "Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor that Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants", blood, (20120000), vol. 120, page 141, XP008180825-
OPPOSITION- CHEN GAO et al., "Combination of Crenolanib with Sorafenib Produces Synergistic Pro- Apoptotic Effects in FLT3-ITD-lnhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations", blood, (20120000), vol. 120, XP008180826-
OPPOSITION- "international nonproprietary names for pharmaceutical substances", WHO Drug Information, (20120000), vol. 26, no. 1, page 57/58, XP055538466-
OPPOSITION- Programme of the American Society of Hematology (ASH) meeting, (20121209), XP055705226-
OPPOSITION- "quizartinib", Wikipedia, (20121218), URL: https://en.wikipedia.org/w/index.php?title=Quizartinib&oldid=528594824, XP055538113-
OPPOSITION- ALLISON GALANIS et al., "Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations", blood, (20120000), vol. 120, page 1341, XP055288113
OPPOSITION- NANCY L. LEWIS et al., "Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers", Journal of Clinical Oncology, (20091101), vol. 27, no. 31, pages 5262 - 5269, XP055538110
SEARCH- Anonymous, "Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations", ClinicalTrials.gov, (20120130), URL: https://clinicaltrials.gov/ct2/show/record/NCT01522469?term=crenolanib&rank=2, (20160718), XP055289345 [Y] 1-41 * the whole document *-
SEARCH- GAO CHEN (CORRESPONDENCE) ET AL, "Combination of crenolanib with sorafenib produces synergistic pro-apoptotic effects in FLT3-ITD-inhibitor-resistant acute myelogenous leukemias with FLT3 mutations", vol. 120, no. 21, ISSN 0006-4971, (20121116), pages 1 - 6, BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, URL: https://ash.confex.com/ash/2012/webprogram/Paper49140.html, (20160716), XP008180826 [X] 1-2,5,8,10-11,13-14,17-18,21-25,28,31,34,36-38,40-41 * the whole document * [Y] 1-41-
SEARCH- SMITH CATHERINE C DR (CORRESPONDENCE) ET AL, "Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutants", vol. 120, ISSN 0006-4971, (20121116), pages 1 - 6, BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, URL: http://www.bloodjournal.org/content/120/21/141, (20160716), XP008180825 [X] 1-2,4-5,7-8,10-11,13-18,21-25,28,30-31,33-34,36-38,40-41 * the whole document * [Y] 1-41-
SEARCH- A.Galanis ET AL, "Abstract 3660: Crenolanib: A next generation FLT3 inhibitor | Cancer Research", Cancer Research, 72 (8 Suppl), doi:10.1158/1538-7445.AM2012-3660, (20120415), URL: http://cancerres.aacrjournals.org/content/72/8_Supplement/3660, (20160713), XP055288113 [X] 1-2,5,8,13-14,17,21-25,28,31,34,37-38,40-41 * the whole document * [Y] 1-41

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents